Agreement between cerebrospinal fluid biomarkers, brain 18-Fluorodeoxyglucose PET, and clinical diagnosis in older adults with cognitive impairment
Background: Clinical practice has advanced toward a combined diagnostic approach that involves clinical criteria and biological markers for Alzheimer’s disease (AD) and other dementias. Objective: To establish the level of diagnostic agreement between an initial clinical diagnosis and cerebrospinal...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2024-01-01
|
| Series: | Revista de Investigación Clínica |
| Subjects: | |
| Online Access: | https://www.clinicalandtranslationalinvestigation.com/frame_esp.php?id=513 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846167309170769920 |
|---|---|
| author | Alberto J. Mimenza-Alvarado Karen G. León-del-Ángel Rodrigo Hernández-Ramírez Juan de D. Rodríguez-Callejas Sara G. Yeverino-Castro Sara G. Aguilar-Navarro |
| author_facet | Alberto J. Mimenza-Alvarado Karen G. León-del-Ángel Rodrigo Hernández-Ramírez Juan de D. Rodríguez-Callejas Sara G. Yeverino-Castro Sara G. Aguilar-Navarro |
| author_sort | Alberto J. Mimenza-Alvarado |
| collection | DOAJ |
| description | Background: Clinical practice has advanced toward a combined diagnostic approach that involves clinical criteria and biological markers for Alzheimer’s disease (AD) and other dementias. Objective: To establish the level of diagnostic agreement between an initial clinical diagnosis and cerebrospinal fluid (CSF) and [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) biomarkers in a cohort of patients from a memory clinic. Methods: This is a observational, retrospective, cohort study conducted at an outpatient memory clinic. Between July 2018 and September 2023, data from adults’ ≥ 55 years with a mild cognitive impairment or dementia diagnosis without etiological diagnosis were obtained, complemented with the evaluation of biomarkers in CSF and [18F] FDG-PET biomarker assessment were included. Kappa coefficients (κ) were used to establish the level of agreement between CSF and [18F] FDG-PET results. Results: Seventy-seven patients had an available [18F] FDG-PET scan, and 25 (32.5%) had both biomarkers. We observed a fair-to-moderate diagnostic agreement between patients’ initial and their final diagnosis in the presence of CSF (κ = 0.233, 95% confidence interval [CI]: −0.099-0.566) and [18F] FDG-PET (κ = 0.451, 95% CI: 0.277-0.625, p < 0.001) results. The Kappa value for diagnostic concordance between [18F] FDG-PET and CSF to differentiate between AD and other dementias was 0.733 (95% CI: 0.425-1.000, p < 0.005). Conclusion: This study demonstrates good agreement between the CSF and FDG-PET biomarkers to differentiate AD from other dementias.
|
| format | Article |
| id | doaj-art-166e7f81afbb41ff8d7e1f1702d1e6f4 |
| institution | Kabale University |
| issn | 0034-8376 2564-8896 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Permanyer |
| record_format | Article |
| series | Revista de Investigación Clínica |
| spelling | doaj-art-166e7f81afbb41ff8d7e1f1702d1e6f42024-11-14T22:01:37ZengPermanyerRevista de Investigación Clínica0034-83762564-88962024-01-0176510.24875/RIC.24000161Agreement between cerebrospinal fluid biomarkers, brain 18-Fluorodeoxyglucose PET, and clinical diagnosis in older adults with cognitive impairmentAlberto J. Mimenza-Alvarado0Karen G. León-del-Ángel1Rodrigo Hernández-Ramírez2Juan de D. Rodríguez-Callejas3Sara G. Yeverino-Castro4Sara G. Aguilar-Navarro5Geriatric Medicine and Neurology Fellowship Program; Department of Geriatrics; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoGeriatric Medicine and Neurology Fellowship Program, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoDepartament of Nuclear Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoDepartment of Geriatrics, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City; Centro de Investigación sobre el Envejecimiento-CINVESTAV Sede Sur, Mexico City, MexicoGeriatric Medicine and Neurology Fellowship Program, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoGeriatric Medicine and Neurology Fellowship Program; Department of Geriatrics; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoBackground: Clinical practice has advanced toward a combined diagnostic approach that involves clinical criteria and biological markers for Alzheimer’s disease (AD) and other dementias. Objective: To establish the level of diagnostic agreement between an initial clinical diagnosis and cerebrospinal fluid (CSF) and [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) biomarkers in a cohort of patients from a memory clinic. Methods: This is a observational, retrospective, cohort study conducted at an outpatient memory clinic. Between July 2018 and September 2023, data from adults’ ≥ 55 years with a mild cognitive impairment or dementia diagnosis without etiological diagnosis were obtained, complemented with the evaluation of biomarkers in CSF and [18F] FDG-PET biomarker assessment were included. Kappa coefficients (κ) were used to establish the level of agreement between CSF and [18F] FDG-PET results. Results: Seventy-seven patients had an available [18F] FDG-PET scan, and 25 (32.5%) had both biomarkers. We observed a fair-to-moderate diagnostic agreement between patients’ initial and their final diagnosis in the presence of CSF (κ = 0.233, 95% confidence interval [CI]: −0.099-0.566) and [18F] FDG-PET (κ = 0.451, 95% CI: 0.277-0.625, p < 0.001) results. The Kappa value for diagnostic concordance between [18F] FDG-PET and CSF to differentiate between AD and other dementias was 0.733 (95% CI: 0.425-1.000, p < 0.005). Conclusion: This study demonstrates good agreement between the CSF and FDG-PET biomarkers to differentiate AD from other dementias. https://www.clinicalandtranslationalinvestigation.com/frame_esp.php?id=51318F-Fluorodeoxyglucose-positron emission tomography. Cerebrospinal fluid. Cognitive impairment. Dementia. Alzheimer’s disease. Brain aging. |
| spellingShingle | Alberto J. Mimenza-Alvarado Karen G. León-del-Ángel Rodrigo Hernández-Ramírez Juan de D. Rodríguez-Callejas Sara G. Yeverino-Castro Sara G. Aguilar-Navarro Agreement between cerebrospinal fluid biomarkers, brain 18-Fluorodeoxyglucose PET, and clinical diagnosis in older adults with cognitive impairment Revista de Investigación Clínica 18F-Fluorodeoxyglucose-positron emission tomography. Cerebrospinal fluid. Cognitive impairment. Dementia. Alzheimer’s disease. Brain aging. |
| title | Agreement between cerebrospinal fluid biomarkers, brain 18-Fluorodeoxyglucose PET, and clinical diagnosis in older adults with cognitive impairment |
| title_full | Agreement between cerebrospinal fluid biomarkers, brain 18-Fluorodeoxyglucose PET, and clinical diagnosis in older adults with cognitive impairment |
| title_fullStr | Agreement between cerebrospinal fluid biomarkers, brain 18-Fluorodeoxyglucose PET, and clinical diagnosis in older adults with cognitive impairment |
| title_full_unstemmed | Agreement between cerebrospinal fluid biomarkers, brain 18-Fluorodeoxyglucose PET, and clinical diagnosis in older adults with cognitive impairment |
| title_short | Agreement between cerebrospinal fluid biomarkers, brain 18-Fluorodeoxyglucose PET, and clinical diagnosis in older adults with cognitive impairment |
| title_sort | agreement between cerebrospinal fluid biomarkers brain 18 fluorodeoxyglucose pet and clinical diagnosis in older adults with cognitive impairment |
| topic | 18F-Fluorodeoxyglucose-positron emission tomography. Cerebrospinal fluid. Cognitive impairment. Dementia. Alzheimer’s disease. Brain aging. |
| url | https://www.clinicalandtranslationalinvestigation.com/frame_esp.php?id=513 |
| work_keys_str_mv | AT albertojmimenzaalvarado agreementbetweencerebrospinalfluidbiomarkersbrain18fluorodeoxyglucosepetandclinicaldiagnosisinolderadultswithcognitiveimpairment AT karengleondelangel agreementbetweencerebrospinalfluidbiomarkersbrain18fluorodeoxyglucosepetandclinicaldiagnosisinolderadultswithcognitiveimpairment AT rodrigohernandezramirez agreementbetweencerebrospinalfluidbiomarkersbrain18fluorodeoxyglucosepetandclinicaldiagnosisinolderadultswithcognitiveimpairment AT juandedrodriguezcallejas agreementbetweencerebrospinalfluidbiomarkersbrain18fluorodeoxyglucosepetandclinicaldiagnosisinolderadultswithcognitiveimpairment AT saragyeverinocastro agreementbetweencerebrospinalfluidbiomarkersbrain18fluorodeoxyglucosepetandclinicaldiagnosisinolderadultswithcognitiveimpairment AT saragaguilarnavarro agreementbetweencerebrospinalfluidbiomarkersbrain18fluorodeoxyglucosepetandclinicaldiagnosisinolderadultswithcognitiveimpairment |